Diabetes News

PHILADELPHIA — Prediabetes is a high-risk state associated with substantial morbidity and mortality, yet consensus is needed regarding an “optimal” definition to better identify who could benefit from interventions, according to a speaker.

PHILADELPHIA — In this Healio video exclusive, Yehuda Handelsman, MD, FACP, FNLA, FASCP, MACE, co-chair of the Heart in Diabetes CME Conference, discusses the mission and purpose of the meeting.

Kidney disease does not influence the benefits of the SGLT2 inhibitor empagliflozin on major HF events, even in patients at high renal risk, according to a new analysis of the EMPEROR-Pooled study.

SEATTLE — Providers treating people with type 2 diabetes should take a complication-centric approach for determining first-line pharmacotherapy, according to a consensus statement.

SEATTLE — The rate of deaths attributed to vascular complications increased from 2001 to 2020 for adults with diabetes in the U.S., with the rise mainly due to an increase in deaths from diabetic nephropathy, according to a speaker.

Adults with type 2 diabetes, chronic kidney disease or both conditions have high rates of hospital admissions and ED visits due in part to a low uptake of medications and a lack of engagement with routine assessments, researchers reported.

AUSTIN, Texas — Results presented here showed that combining SGLT2 inhibitors and mineralocorticoid receptor antagonists was effective in reducing the urinary albumin creatinine ratio in patients with type 2 diabetes.

Among patients with type 2 diabetes and chronic kidney disease, finerenone treatment may provide cardiovascular benefits, according to data published in the Clinical Journal of the American Society of Nephrology.

Compared with glucagon-like peptide-1 receptor agonists, patients with chronic kidney disease and type 2 diabetes experienced increased risks when taking SGLT2 inhibitors, according to published data.

Among patients with type 2 diabetes and albuminuric chronic kidney disease, canagliflozin reduced kidney and cardiovascular events independent of age or sex, according to data published in the American Journal of Kidney Diseases.